Maryland Medical Research Institute Report issue

Academic/Hospital Phase 3

Organization Overview

First Clinical Trial
1983
NCT00000505
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
1992

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Anemia (Phase 3)

Anemia, Sickle Cell (Phase 3)

Cardiovascular Diseases (Phase 3)

Coronary Disease (Phase 3)

Heart Diseases (Phase 3)

Hematologic Diseases (Phase 3)

Hemoglobinopathies (Phase 3)

Infarction (Phase 3)

Ischemia (Phase 3)

Myocardial Infarction (Phase 3)

Myocardial Ischemia (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 5